ClinicalTrials.gg
CompletedNCT02885610Updated Mar 4, 2020

Study of RC18 Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus(SLE)

A Phase 2 interventional study of Placebo plus standard therapy and RC18 80 mg plus standard therapy in Systemic Lupus Erythematosus, sponsored by RemeGen Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2020-03-04.

Sponsored by RemeGen Co., Ltd. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
249
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies testing telitacicept in Lupus Erythematosus, Systemic — 6 open to participants now, 7 under way, 1 of them phase 3. telitacicept · Lupus Erythematosus, Systemic.

Enrollment
2nd of 13
249 · median 64
Started
2015
the only one that year
Phase 2
3 of 13
2 open now
Registered
1st of 13
by date
Lead sponsor
4 of 13
RemeGen Co., Ltd.

Among the 13 studies testing telitacicept in Lupus Erythematosus, Systemic, this one is the 2nd largest by enrollment, is the only one that started in 2015, is one of 3 in phase 2, and was the 1st registered.

Lupus Erythematosus, Systemic

1,210 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.

Browse Lupus Erythematosus, Systemic studies →

Open to participants now

6 of the 13 studies testing telitacicept in Lupus Erythematosus, Systemic are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About telitacicept

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 93 (33%) set no upper age limit and 161 (57%) stop at 75 or younger; 54 take children under 18; 33 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies testing telitacicept in Lupus Erythematosus, Systemic, or all of them as a file.
02

Study summary

The purpose of this study is to initially access the safety and effectivity of RC18 combined with standard treatment and Placebo combined with standard therapy in subjects with Moderate to severe SLE, Besides ,to provide dose basis for follow-up clinical trials.

03

Conditions studied

  • Systemic Lupus Erythematosus
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Active SLE disease,and at least according with 4 of the 11 items of the American College of Rheumatology (ACR) criteria 1997.
  • Age \& Gender: Male or female between 18 and 65 years of age inclusive,and the sex ratio is not limited
  • Signed form,willing or able to participate in all required study evaluations and procedures.
  • SELENA-SLEDAI(Safety of Estrogens in Lupus Erythematosus National Assessment SLE Disease Activity Index) score ≥ 8 during the screening period.and if there is hypocomlement or the Anti-dsDNA score, SELENA-SLEDAI disease activity score should be at least 6 at screening .
  • Autoantibody-positive
  • on a stable SLE treatment regimen for at least 30 days prior to Day 1, which consisted of any of the following (alone or in combination): cortical hormone,anti-malarials,non-steroidal anti inflammatory drugs (NSAIDs),or any and immunomodulator therapy(i.e.,azathioprine,mycophenolate ,cyclophosphamide,methotrexate,leflunomide, Tacrolimus ,ciclosporin ).

Exclusion criteria

Exclusion Criteria:

  • Severe lupus nephritis within two months(designed as:Urine protein>6g/24h or serum creatinine ( SCr)>2.5mg/dL or 221umol/L ) or needing for hemodialysis or recepting high dose cortical hormone ≥14 days( metacortandracin>100mg/d or equivalent)
  • Central nervous system disease caused by SLE or non SLE within two months (including epilepsy, mental disease,organic encephalopathy syndrome,cerebrovascular accident, encephalitis, central nervous system vasculitis);
  • there are serious heart, liver, kidney and other important organs and blood, endocrine system diseases and medical history;

Evaluation criteria for severity :

  1. (ALT)or aspartate aminotransferase (AST) ≥2 (ULN);
  2. (Ccr)\<30ml/min;
  3. White Blood Cell Count(WBCs)\<2.5x 10(9)/L;
  4. \<85g/L;
  5. \<50x 10(9)/L.

    • Have a historically active hepatitis or active hepatitis or medical history, :Patients with positive HBsAg are excluded.;: Patients with hepatitis C antibody positive are excluded;
    • Immune deficiency, uncontrolled severe infection and patients with active or recurrent peptic ulcer;
    • Pregnant , lactating women and men or women who have birth plans in the past 12 months ;
    • Have a history of allergic reaction to human biological medicines.
    • Receipt of within 1 month;
    • Have participated in any clinical trial in the first 28 days of the initial screening or 5 times half-life period of the study compound (taking the time for the elderly).
    • Have received treatment with B cell targeted therapy such as Rituximab or Epratuzumab etc.
    • Receipt of anti-tumor necrosis factor、interleukin receptor antagonist;
    • Receipt of IV immunoglobulin(IVIG),prednisone>100mg/d more than 14 days or plasma exchange;
    • There are active infections (such as herpes zoster, (HIV) virus infection, active tuberculosis, etc.) during the screening period;
    • Patients have depression or the significant suicide ideation;
    • Investigator considers candidates not appropriating for the study.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
249 participants (actual)

Study arms

  • Placebo comparator
    Placebo Comparator

    Placebo SC plus standard therapy; placebo once weekly ,and total of 48 doses

    Biological: Placebo plus standard therapy

  • Experimental
    RC18 80 mg plus standard therapy

    RC18 80 mg/kg SC plus standard therapy RC18 80 mg SC once weekly X 48 doses

    Biological: RC18 80 mg plus standard therapy

  • Experimental
    RC18 160 mg plus standard therapy

    RC18 160 mg/kg SC plus standard therapy RC18 160 mg SC once weekly X 48 doses

    Biological: RC18 160 mg plus standard therapy

  • Experimental
    RC18 240 mg plus standard therapy

    RC18 240 mg/kg SC plus standard therapy RC18 240 mg SC once weekly X 48 doses

    Biological: RC18 240 mg plus standard therapy

Interventions

  • BiologicalPlacebo plus standard therapy

    Standard therapy comprises any of the following (alone or in combination): corticosteroids, antimalarials, non-steroidal anti-inflammatory drugs (NSAIDs), and immunosuppressive and immunomodulator therapy(i.e.,azathioprine,mycophenolate ,cyclophosphamide,methotrexate,leflunomide, Tacrolimus ,ciclosporin )

    Also known as: Standard therapy

  • BiologicalRC18 80 mg plus standard therapy

    Drug page: Telitacicept

    Standard therapy comprises any of the following (alone or in combination): corticosteroids, antimalarials, non-steroidal anti-inflammatory drugs (NSAIDs), and immunosuppressive and immunomodulator herapy(i.e.,azathioprine,mycophenolate ,cyclophosphamide,methotrexate,leflunomide, Tacrolimus ,ciclosporin )

    Also known as: Standard therapy

  • BiologicalRC18 160 mg plus standard therapy

    Drug page: Telitacicept

    Standard therapy comprises any of the following (alone or in combination): corticosteroids, antimalarials, non-steroidal anti-inflammatory drugs (NSAIDs), and immunosuppressive and immunomodulator herapy(i.e.,azathioprine,mycophenolate ,cyclophosphamide,methotrexate,leflunomide, Tacrolimus ,ciclosporin )

    Also known as: Standard therapy

  • BiologicalRC18 240 mg plus standard therapy

    Drug page: Telitacicept

    Standard therapy comprises any of the following (alone or in combination): corticosteroids, antimalarials, non-steroidal anti-inflammatory drugs (NSAIDs), and immunosuppressive and immunomodulator therapy(i.e.,azathioprine,mycophenolate ,cyclophosphamide,methotrexate,leflunomide, Tacrolimus ,ciclosporin )

    Also known as: Standard therapy

06

What researchers measure

Primary outcomes

  1. SLE Responder Index (SRI) Response Rate

    At Week 48, the percent of subjects with ≥ 4 point reduction from baseline in SELENA SLEDAI score and increasing no more than 0.3 points in PGA and no new BILAG A organ domain score or 1 new BILAG B organ domain scores compared with baseline at the time of assessment.

    Time frame: Week 48

Secondary outcomes

  1. Percent of subjects with ≥ 4 point reduction from baseline in SELENA SLEDAI score

    Time frame: Week 48

Other outcomes

  1. Mean Change From Baseline in PGA

    Time frame: Week 48

  2. Percent of Subjects Whose Average Prednisone Dose Has Been Reduced by ≥ 25% From Baseline or ≤ 7.5 mg/Day During Weeks 44 Through 48

    Time frame: Week 44 through 48

  3. Mean Change From Baseline in Serological Examination Index(IgG、IgA、IgM) CD19+、Anti-dsDNA 、Complent C3、C4

    Time frame: week 48

07

Study locations

1 site
  • Peking Union Medical College Hospital
    Beijing, Beijing, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2015, a primary completion of Jun 2019 and a completion of Jul 2019. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 26, 2016
First posted
Aug 31, 2016
Start
Dec 2015
Primary completionActual
Jun 11, 2019
CompletionActual
Jul 9, 2019
Last update
Mar 4, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 4, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02885610
Lead sponsor
RemeGen Co., Ltd.
Responsible party
Sponsor
First posted
Aug 31, 2016
Start date
Dec 2015
Primary completion
Jun 11, 2019
Completion
Jul 9, 2019
Last update
Mar 4, 2020

Study contacts

Fengchun Zhang
principal investigator · Peking Union Medical College Hospital

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Telitacicept

Start the discussion